Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCCS: Sorafenib Expanded Access in Advanced RCC
NCT00111020Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of sorafenib in renal cell carcinoma (RCC), sponsored by Bayer. Primary endpoint: Safety parameters. Started Jun 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00111020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111020.